ArticleJournal of the American College of Cardiology2024
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems.
Article in Journal of the American College of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07434791 (GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease
Who cites it
19 citing papers in PubMed.
- A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease.Cardiovascular diabetology · 2025Trial
- Integrating Clinical Decision Support Systems in CKD Management.Kidney international reports · 2026Article
- Prescription patterns of SGLT2 inhibitors in patients admitted to a tertiary health service with heart failure with reduced ejection fraction: an opportunity to improve.Internal medicine journal · 2026Article
- Clinical Implications of Missed CKD Diagnosis in Adults with and without Diabetes Mellitus.Journal of the American Society of Nephrology : JASN · 2026Article
- Utilization Patterns and Barriers to Sodium-Glucose Cotransporter-2 Inhibitor Prescription in Patients with Heart Failure: Real-World Evidence from Saudi Arabia.Cardiology and therapy · 2026Article
- Missing Opportunity for Nephroprotective Therapy in Patients With Non-Dialysis CKD Under Stable Nephrology Care.Kidney international reports · 2026Article
- Epidemiology of cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease.JAMA network open · 2026Article
- Practice Variation in Prescribing SGLT2-Inhibitors: A Population-Based Analysis from Alberta, Canada.CJC open · 2026Article
- Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex.Diabetes, obesity & metabolism · 2026Observational
- From global guidelines for cardio-kidney-metabolic diseases management to national implementation: perspectives from the guideline workshop taskforce.Cardiovascular diabetology · 2026Article
- Seven-day ECG Holter vs. 14-day event Holter in the detection of life-threatening ventricular arrhythmias, new atrial fibrillation, and silent ischemia among heart failure patients from social exclusion regions.Cardiology journal · 2026Article
- Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study.Diabetes, obesity & metabolism · 2025Article
- Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system.American journal of preventive cardiology · 2025Article
- Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Meeting People Where They Are: Improving Diabetes Care and Outcomes Through Education and Collaboration.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Enhancing the use of sodium-glucose cotransporter-2 inhibitors in type-2 diabetic patients with chronic kidney disease, through a key performance indicator program.Qatar medical journal · 2025Article
- Effectiveness and use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure (HF) hospitalizations, recurrent cardiovascular events, and chronic kidney disease (CKD) progression, and thus constitute a Class 1a recommendation in people with diabetes and atherosclerotic cardiovascular disease, HF, or CKD and in people with severe albuminuria or HF, regardless of diabetes status.
objectivesThe purpose of this study was to comprehensibly characterize the rate of SGLT2 inhibitor prescriptions among people with a Class 1a recommendation for SGLT2 inhibitor use.
methodsAmong 3,189,827 adults from 28 U.S. health systems within Optum Labs Data Warehouse between April 1, 2022, and March 31, 2023, we assessed SGLT2 inhibitor prescription rates, stratified by presence of diabetes and Class 1a recommendation.
resultsAmong 716,387 adults with diabetes, 63.4% had a Class 1a recommendation for SGLT2 inhibitor therapy. There was little difference by Class 1a recommendation status (present: 11.9%; 95% CI: 11.9%-12.0% vs absent: 11.4%; 95% CI: 11.3%-11.6%; standardized mean difference: 1.3%). Among 2,473,440 adults without diabetes, 6.2% had a Class 1a recommendation for SGLT2 inhibitor therapy, and 3.1% (3.0%-3.2%) of those received a prescription. Internists/family practitioners initiated SGLT2 inhibitor prescriptions most commonly among people with diabetes, whereas specialists initiated SGLT2 inhibitor prescriptions most commonly among people without diabetes. No health system had >25% SGLT2 inhibitor prescription rate among people with a Class 1a recommendation. Health systems with higher proportions of patients with commercial insurance and lower proportions with Medicare had higher SGLT2 inhibitor prescription rates.
conclusionsIn this analysis of U.S. data from 2022 to 2023, SGLT2 inhibitor prescription among people with a Class 1a recommendation is low. Interventions are needed to increase uptake of guideline-recommended SGLT2 inhibitor use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.